Prevalence and Risk of Severe Cognitive Impairment in Advanced Chronic Kidney Disease

Christine M. Burns, David S. Knopman, David E. Tupper, Cynthia S. Davey, Yelena M. Slinin, Kamakshi Lakshminarayan, Rebecca C. Rossom, Sarah L. Pederson, David T. Gilbertson, Anne M. Murray

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Background Our primary goal is to describe the prevalence, severity, and risk of cognitive impairment (CI) by estimated glomerular filtration rate (eGFR, in mL/min/1.73 m 2) in a cohort enriched for advanced chronic kidney disease (CKD; eGFR < 45), adjusting for albuminuria, as measured by urine albumin-to-creatinine ratio (UACR, in mg/g). As both eGFR and albuminuria are associated with CI risk in CKD, we also seek to determine the extent that eGFR remains a useful biomarker for risk of CI in those with CKD and concomitant albuminuria. Methods Chi-square tests measured the prevalence of severe CI and mild cognitive impairment (MCI) by eGFR level. Logistic regression models and generalized linear models measured risk of CI by eGFR, adjusted for UACR. Results Participants were 574 adults with a mean age of 69; 433 with CKD (eGFR < 60, nondialysis) and 141 controls (eGFR ≥ 60). Forty-eight percent of participants with CKD had severe CI or MCI. The prevalence of severe CI was highest (25%) in those with eGFR < 30. eGFR < 30 was only associated with severe CI in those without albuminuria (UACR < 30; OR = 3.3; p =.02) and was not associated with MCI in similar models. Conclusions One quarter of those with eGFR < 30 had severe CI. eGFR < 30 was associated with over threefold increased odds of severe CI in those with UACR < 30, but not with UACR > 30, suggesting that eGFR < 30 is a valid biomarker for increased risk of severe CI in those without concomitant albuminuria.

Original languageEnglish (US)
Pages (from-to)393-399
Number of pages7
JournalJournals of Gerontology - Series A Biological Sciences and Medical Sciences
Issue number3
StatePublished - Mar 2 2018

Bibliographical note

Funding Information:
Address correspondence to: Christine M. Burns, PhD, Neuropsychology Research Fellow, Minneapolis Medical Research Foundation, Hennepin County Medical Center, 701 Park Ave S2.306, Minneapolis, MN 55415. E-mail:

Funding Information:
1Minneapolis Medical Research Foundation, Hennepin County Medical Center, Minnesota. 2Department of Neurology, University of Minnesota, Minneapolis. 3Department of Neurology, Mayo Clinic, Rochester, Minnesota. 4Department of Psychology and Neuropsychology, Hennepin County Medical Center, Minneapolis, Minnesota. 5Biostatistical Design and Analysis Center, University of Minnesota Clinical and Translational Science Institute, Minneapolis. 6Minneapolis VA Health Care Center, Minnesota. 7Department of Medicine, University of Minnesota, Minneapolis. 8Division of Epidemiology and Community Health, University of Minnesota School of Public Health, Minneapolis. 9HealthPartners Institute, Bloomington, Minnesota. 10Chronic Disease Research Group, Minneapolis Medical Research Foundation, Hennepin County Medical Center, Minnesota. 11Geriatrics Division, Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota.

Funding Information:
This work was supported by National Institute on Aging Grant # R01 AG03755, Satellite Health Inc., the Minneapolis Medical Research Foundation and grant number UL1TR000114 from the National Center for Research Resources, National Institutes of Health.

Publisher Copyright:
© The Author(s) 2017. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved.


  • Cognitive aging
  • Dementia
  • Epidemiology
  • Renal


Dive into the research topics of 'Prevalence and Risk of Severe Cognitive Impairment in Advanced Chronic Kidney Disease'. Together they form a unique fingerprint.

Cite this